Anti-Factor B Antibodies and Acute Postinfectious GN in Children.
complement
glomerulonephritis
pediatrics
Journal
Journal of the American Society of Nephrology : JASN
ISSN: 1533-3450
Titre abrégé: J Am Soc Nephrol
Pays: United States
ID NLM: 9013836
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
28
08
2019
accepted:
26
12
2019
pubmed:
9
2
2020
medline:
11
11
2020
entrez:
9
2
2020
Statut:
ppublish
Résumé
The pathophysiology of the leading cause of pediatric acute nephritis, acute postinfectious GN, including mechanisms of the pathognomonic transient complement activation, remains uncertain. It shares clinicopathologic features with C3 glomerulopathy, a complement-mediated glomerulopathy that, unlike acute postinfectious GN, has a poor prognosis. This retrospective study investigated mechanisms of complement activation in 34 children with acute postinfectious GN and low C3 level at onset. We screened a panel of anticomplement protein autoantibodies, carried out related functional characterization, and compared results with those of 60 children from the National French Registry who had C3 glomerulopathy and persistent hypocomplementemia. All children with acute postinfectious GN had activation of the alternative pathway of the complement system. At onset, autoantibodies targeting factor B (a component of the alternative pathway C3 convertase) were found in a significantly higher proportion of children with the disorder versus children with hypocomplementemic C3 glomerulopathy (31 of 34 [91%] versus 4 of 28 [14%], respectively). In acute postinfectious GN, anti-factor B autoantibodies were transient and correlated with plasma C3 and soluble C5b-9 levels. We demonstrated that anti-factor B antibodies enhance alternative pathway convertase activity These findings elucidate the pathophysiologic mechanisms underlying acute postinfectious GN by identifying anti-factor B autoantibodies as contributing factors in alternative complement pathway activation. At onset of a nephritic syndrome with low C3 level, screening for anti-factor B antibodies might help guide indications for kidney biopsy to avoid misdiagnosed chronic glomerulopathy, such as C3 glomerulopathy, and to help determine therapy.
Sections du résumé
BACKGROUND
The pathophysiology of the leading cause of pediatric acute nephritis, acute postinfectious GN, including mechanisms of the pathognomonic transient complement activation, remains uncertain. It shares clinicopathologic features with C3 glomerulopathy, a complement-mediated glomerulopathy that, unlike acute postinfectious GN, has a poor prognosis.
METHODS
This retrospective study investigated mechanisms of complement activation in 34 children with acute postinfectious GN and low C3 level at onset. We screened a panel of anticomplement protein autoantibodies, carried out related functional characterization, and compared results with those of 60 children from the National French Registry who had C3 glomerulopathy and persistent hypocomplementemia.
RESULTS
All children with acute postinfectious GN had activation of the alternative pathway of the complement system. At onset, autoantibodies targeting factor B (a component of the alternative pathway C3 convertase) were found in a significantly higher proportion of children with the disorder versus children with hypocomplementemic C3 glomerulopathy (31 of 34 [91%] versus 4 of 28 [14%], respectively). In acute postinfectious GN, anti-factor B autoantibodies were transient and correlated with plasma C3 and soluble C5b-9 levels. We demonstrated that anti-factor B antibodies enhance alternative pathway convertase activity
CONCLUSIONS
These findings elucidate the pathophysiologic mechanisms underlying acute postinfectious GN by identifying anti-factor B autoantibodies as contributing factors in alternative complement pathway activation. At onset of a nephritic syndrome with low C3 level, screening for anti-factor B antibodies might help guide indications for kidney biopsy to avoid misdiagnosed chronic glomerulopathy, such as C3 glomerulopathy, and to help determine therapy.
Identifiants
pubmed: 32034108
pii: ASN.2019080851
doi: 10.1681/ASN.2019080851
pmc: PMC7191928
doi:
Substances chimiques
Autoantibodies
0
Complement C3
0
Complement C3 Nephritic Factor
0
Complement Factor B
EC 3.4.21.47
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
829-840Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2020 by the American Society of Nephrology.
Références
Adv Anat Pathol. 2012 Sep;19(5):338-47
pubmed: 22885383
Clin J Am Soc Nephrol. 2013 Apr;8(4):554-62
pubmed: 23307876
Kidney Int. 2015 Nov;88(5):1153-60
pubmed: 26221755
Isr Med Assoc J. 2016 Jun;18(6):336-40
pubmed: 27468526
Pediatr Nephrol. 2010 May;25(5):947-51
pubmed: 20108004
J Am Soc Nephrol. 2004 Mar;15(3):787-95
pubmed: 14978182
Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):240-5
pubmed: 17182750
Clin J Am Soc Nephrol. 2018 Mar 7;13(3):406-413
pubmed: 29326307
Am J Kidney Dis. 2016 Dec;68(6):944-948
pubmed: 27683044
J Immunol. 2015 Jun 1;194(11):5129-38
pubmed: 25917093
Kidney Int. 2013 Dec;84(6):1079-89
pubmed: 24172683
Nature. 2015 Oct 1;526(7571):68-74
pubmed: 26432245
Hum Mutat. 2010 Jun;31(6):E1445-60
pubmed: 20513133
Nat Rev Nephrol. 2019 Mar;15(3):129-143
pubmed: 30692664
Kidney Int. 2017 Nov;92(5):1232-1241
pubmed: 28712854
Pediatr Int. 2018 Jul;60(7):645-650
pubmed: 29729114
Clin J Am Soc Nephrol. 2019 Mar 7;14(3):364-377
pubmed: 30674459
Nat Immunol. 2009 Jul;10(7):721-7
pubmed: 19503103
J Am Soc Nephrol. 2017 May;28(5):1603-1613
pubmed: 28096309
Kidney Int. 2014 Feb;85(2):450-6
pubmed: 24067430
Kidney Int. 2017 Mar;91(3):539-551
pubmed: 27989322
J Am Soc Nephrol. 2014 Sep;25(9):2053-65
pubmed: 24652797
Kidney Int. 2013 Feb;83(2):293-9
pubmed: 23235567
J Med Genet. 2003 Sep;40(9):676-81
pubmed: 12960213
J Am Soc Nephrol. 2004 Jul;15(7):1785-93
pubmed: 15213266
Kidney Int Suppl (2011). 2012 Jun;2(2):200-208
pubmed: 25018934
Pediatr Nephrol. 2016 Nov;31(11):2079-86
pubmed: 27008643
Clin Infect Dis. 1992 Jan;14(1):251-62
pubmed: 1571441
Science. 2010 Dec 24;330(6012):1816-20
pubmed: 21205667
Blood. 2013 Aug 22;122(8):1487-93
pubmed: 23847193
Kidney Int. 2012 Aug;82(4):454-64
pubmed: 22456601
N Engl J Med. 2011 Dec 15;365(24):2340-2
pubmed: 22168663
Lancet Infect Dis. 2005 Nov;5(11):685-94
pubmed: 16253886
J Immunol. 1979 Aug;123(2):755-8
pubmed: 379217
Nat Struct Mol Biol. 2007 Mar;14(3):224-8
pubmed: 17310251